Evotec

Evotec is a German company operating in the pharmaceutical sector, with its core business focused on drug development. The organization's activities are centered on the research and development of therapeutic compounds, serving the broader healthcare and biotechnology markets. Its operational footprint is global, with business continuity maintained across its international sites during operational disruptions. The company's work places it within the highly regulated drug development industry, where data integrity and secure research processes are critical to its operations and partnerships.

In April 2023, Evotec experienced a significant cyberattack that compromised its IT systems. In response, the company proactively disconnected all its IT systems from the internet to prevent potential data corruption or unauthorized access. This security measure, while necessary, directly caused production delays and slower response times for its collaborative partners. Forensic experts were engaged to examine the affected systems thoroughly. The company upheld business continuity at its worldwide locations during the investigation and restoration period. Evotec did not reconnect its network until the forensic examination was fully completed and enhanced security plans were implemented to address the vulnerabilities exploited in the attack. The incident underscored the operational risks faced by entities in the life sciences sector and the direct impact such security events can have on research timelines and partner relationships. The company's public communication confirmed the attack and its consequential impact on operational tempo.